Division of Translational Research & Applied Statistics
Director: Gina R. Petroni, Ph.D.
The Division of Translational Research and Applied Statistics (TRAppS) provides an analytical infrastructure for basic, clinical, and translational research, specifically in cancer. We are the academic home of the Biostatistics Shared Resource for the UVA Cancer Center.
- Members use their expertise to help develop, foster and lead discovery and innovation for translational science across the University of Virginia.
- The Division has statistical expertise in pre-clinical studies and in all phases of clinical research with a particular emphasis on methodology related to early stage clinical trials.
Early phase study design
We design innovative clinical trials by developing and implementing novel statistical methodology that will answer research questions being posed in contemporary early development trials. We are part of a national research effort to change the way early phase trials in oncology are done through the Center for Early Phase Trials (CEPT).
Preclinical experiments Middle to late stage study design Propose and implement appropriate study designs to meet the study objectives, including sample size determination and statistical analysis plans Clinical trial implementation and monitoring Grant proposals Data Analysis Education
Middle to late stage study design
Propose and implement appropriate study designs to meet the study objectives, including sample size determination and statistical analysis plans
Clinical trial implementation and monitoring
Recent Division Highlights
- Dr. Conaway and colleague’s paper “Minimizing Glucose Excursions (GEM) With Continuous Glucose Monitoring in Type 2 Diabetes: A Randomized Clinical Trial” has been selected as the Journal of the Endocrine Society Featured Article for the week of Oct 28.
- Congratulations to Drs. Conaway & Horton, who are part of the team who received the 2020 Dean’s Award for Excellence in Research: Team Science. The award was given to the team led by Drs. Tom Loughran & Mark Kester for their work on the recently funded P01 award from NIH “TARGETED SPHINGOLIPID METABOLISM FOR TREATMENT OF AML.”
- Dr. Wages’ NIH/NCI R01 application entitled “Dose-finding designs for late-onset toxicities” scored in the 3rd percentile (October 2020 review).